Such results can help validate the use of USP14 selective inhibitors, such as b-AP15, or knockdown by shRNA in novel targeted cancer therapies and suggest that USP14 is a potential therapeutic target for OSCC [85]. This evidence concerns the gene USP14 and cancer.